Illumina TruSight Oncology 500 ctDNA v2

Illumina has launched an update to its TruSight Oncology 500 ctDNA research assay. Improvements include a faster turnaround time of less than four days, higher sensitivity with lower cell-free DNA input requirements, and a more streamlined workflow. The assay enables analysis from as little as 5 to 30 ng of cfDNA input. At 20 ng input, it shows more than 95 percent analytical sensitivity with greater than 99 percent specificity. At 10 ng input, it shows more than 95 percent sensitivity for hot-spot mutations with greater than 99 percent specificity